Insights in osteoarthritis from the perspectives of evidence-based medicine and authors' own experience
DOI: 10.32364/2587-6821-2023-7-3-167-173
E.S. Zhugrova, I.B. Belyaeva, R.R. Samigullina
I.I. Mechnikov North-Western State Medical University, St. Petersburg, Russian Federation
Osteoarthritis (OA) is a chronic heterogenic progressive disease involving the deterioration of the cartilage tissue within joints, bone remodeling and the development of osteophytes that cause such clinical manifestations as pain, stiffness, edema and reduced joint function. The review elucidates modern views on the pathogenesis of OA and the up-to-date approaches to its diagnostics and treatment. Today, the emphasis is made on relieving pain and improving the quality of life of patients with OA. Symptomatic slow-acting drugs for osteoarthritis (SYSADOA) are used in OA clinical practice. The drugs of this class have beneficial effects on OA symptoms and their long-term use exerts disease-modifying action. SYSADOA are recommended for use as the first-line therapy and the treatment of choice in OA. Chondroitin sulfate (CS) is considered as a SYSADOA drug whose effectiveness has been proven in multiple clinical trials. CS is included in the EULAR recommendations for the treatment of patients with OA. The use of chondroitin has been shown to reduce pain and improve mobility of the affected joints. The authors present a clinical report of CS beneficial effects in a patient with OA.
Keywords: osteoarthritis, pathogenesis, treatment, quality of life, SYSADOA, chondroitin sulfate.
For citation: Zhugrova E.S., Belyaeva I.B., Samigullina R.R. Insights in osteoarthritis from the perspectives of evidence-based medicine and authors' own experience. Russian Medical Inquiry. 2023;7(3):167–173 (in Russ.). DOI: 10.32364/2587-6821-2023-7-3-167-173.
2. Katz J.N., Arant K.R., Loeser R.F. Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review. JAMA. 2021;325(6):568–578. DOI: 10.1001/jama.2020.22171.
3. Abramoff B., Caldera F.E. Osteoarthritis: Pathology, Diagnosis, and Treatment Options. Med Clin North Am. 2020;104(2):293–311. DOI: 10.1016/j.mcna.2019.10.007.
4. Sabha M., Hochberg M.C. Non-surgical management of hip and knee osteoarthritis; comparison of ACR/AF and OARSI 2019 and VA/DoD 2020 guidelines. Osteoarthr Cartil Open. 2021;4(1):100232. DOI: 10.1016/j.ocarto.2021.100232.
5. Molnar V., Matišić V., Kodvanj I. et al. Cytokines and Chemokines Involved in Osteoarthritis Pathogenesis. Int J Mol Sci. 2021;22(17):9208. DOI: 10.3390/ijms22179208.
6. Hu Q., Ecker M. Overview of MMP-13 as a Promising Target for the Treatment of Osteoarthritis. Int J Mol Sci. 2021;22(4):1742. DOI: 10.3390/ijms22041742.
7. Martel-Pelletier J., Maheu E., Pelletier J.P. et al. A new decision tree for diagnosis of osteoarthritis in primary care: international consensus of experts. Aging Clin Exp Res. 2019;31(1):19–30. DOI: 10.1007/s40520-018-1077-8.
8. Bruyère O., Honvo G., Veronese N. et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337–350. DOI: 10.1016/j.semarthrit.2019.04.008.
9. Arden N.K., Perry T.A., Bannuru R.R. et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nat Rev Rheumatol. 2021;17(1):59–66. DOI: 10.1038/s41584-020-00523-9.
10. Rausch Osthoff A.K., Niedermann K., Braun J. et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77(9):1251–1260. DOI: 10.1136/annrheumdis-2018-213585.
11. Bannuru R.R., Osani M.C., Vaysbrot E.E. et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578–1589. DOI: 10.1016/j.joca.2019.06.011.
12. McAlindon T.E., Bannuru R.R., Sullivan M.C. et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22(3):363–388. DOI: 10.1016/j.joca.2014.01.003.
13. Geenen R., Overman C.L., Christensen R. et al. EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77(6):797–807. DOI: 10.1136/annrheumdis-2017-212662.
14. Mathieu S., Soubrier M., Peirs C. et al. A Meta-Analysis of the Impact of Nutritional Supplementation on Osteoarthritis Symptoms. Nutrients. 2022;14(8):1607. DOI: 10.3390/nu14081607.
15. Kolasinski S.L., Neogi T., Hochberg M.C. et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020;72(2):149–162. DOI: 10.1002/acr.24131.
16. Anil U., Markus D.H., Hurley E.T. et al. The efficacy of intra-articular injections in the treatment of knee osteoarthritis: A network meta-analysis of randomized controlled trials. Knee. 2021;32:173–182. DOI: 10.1016/j.knee.2021.08.008.
17. Simental-Mendía M., Sánchez-García A., Vilchez-Cavazos F. et al. Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis of randomized placebo-controlled trials. Rheumatol Int. 2018;38(8):1413–1428. DOI: 10.1007/s00296-018-4077-2.
18. Henrotin Y., Marty M., Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas. 2014;78(3):184–187. DOI: 10.1016/j.maturitas.2014.04.015.
19. Zhu X., Sang L., Wu D. et al. Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta-analysis of randomized controlled trials. J Orthop Surg Res. 2018;13(1):170. DOI: 10.1186/s13018-018-0871-5.
20. Zegels B., Crozes P., Uebelhart D. et al. Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis Cartilage. 2013;21(1):22–27. DOI: 10.1016/j.joca.2012.09.017.
21. Kloppenburg M., Kroon F.P., Blanco F.J. et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019;78(1):16–24. DOI: 10.1136/annrheumdis-2018-213826.
22. Vitaloni M., Botto-van Bemden A., Sciortino Contreras R.M. et al. Global management of patients with knee osteoarthritis begins with quality of life assessment: a systematic review. BMC Musculoskelet Disord. 2019;20(1):493. DOI: 10.1186/s12891-019-2895-3.
23. Veronese N., Cooper C., Bruyère O. et al. Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations. Drugs. 2022;82(13):1347–1355. DOI: 10.1007/s40265-022-01773-5.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
